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INTRODUCTION
Varicella zoster virus (VZV), a ubiquitous human alpha-herpes virus, 
is a member of the Herpesviridae family(1). Following primary infection 
with VZV (chicken pox), the immune response protects against 
reinfection on re-exposure to VZV. However, when cell-mediated 
immunity declines through aging or immunosuppression, VZV can 
reactivate in the sensory ganglia, causing herpes zoster (HZ), which 
is the secondary (recurrent) form of the disease(2,3). 
Age also appears to be important in the natural history of HZ 
infection. It is known, for example, that HZ affects >50% of individuals 
by 80 years of age(4) and that there is an increased prevalence of 
impaired immunity due to systemic disorders or immunosuppressive 
therapy(5,6). Considering that the number of people aged ≥60 years is 
projected to double over coming decades, the number of HZ cases 
is also expected to increase substantially.
A diagnosis of HZ is primarily based on the history and clinical 
findings(7), with laboratory confirmation unnecessary in all but 
specific patient populations(8). Definitive proof of HZ requires viral 
antigen detection using direct fluorescent antibody or polymerase 
chain reaction (PCR). The virus can be detected in cutaneous lesions, 
cerebrospinal fluid (CSF), bronchoalveolar lavage fluid, saliva, and 
aqueous humor, as well as in blood, corneal, retinal, and vitreous 
fluids(9-13). Although direct fluorescent antibody is more frequently 
used for the diagnosis of VZV, it is less specific and sensitive than 
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PCR, and even less effective for early diagnosis. PCR of the CSF can 
detect VZV within 1 week of infection onset and can remain positive 
for 14-50 days(10,14).
HZ ophthalmicus (HZO) is 20 times more common when com-
pared with either mandibular or maxillary infection(2,15), being exceeded 
only by thoracic zoster(16). As shown in table 1, there are several 
potential complications associated with HZO, and these can affect 
either the skin, anterior ocular segment, optic nerve, retina, or central 
nervous system(7). HZ infection can also occur in the absence of cuta-
neous involvement(17,18), as is seen in zoster sine herpete.
HZO is a serious and unpredictable disease that should always be 
treated with nucleoside analogs at the first sign of infection, prefera-
bly within 72 h of prodromal symptoms(19,20). Early acyclovir treatment 
(800 mg, five times a day) can reduce acute pain and the incidence of 
eye complications from 50% to 20%-30%(21). Valacyclovir (1000 mg t.i.d.) 
and famciclovir (500 mg t.i.d.), which are therapeutically equivalent, 
can also be used, and published recommendations on the manage-
ment of HZ agree that antiviral therapy with either drug is preferable 
to acyclovir(20,22). Valacyclovir and famciclovir provide higher plasma 
concentrations of the acyclic nucleoside analog required to inhibit 
VZV, thus reducing acute viral shedding and minimizing neural dama-
ge. Further, these drugs have simpler dosing regimens and are asso-
ciated with higher treatment adherence. Foscarnet is an alternative 
treatment option in special cases(23).
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In addition to antiviral therapy, corticosteroid eye drops are re-
commended for severe inflammation caused by HZO, such as uveitis, 
and an oral corticosteroid may eventually be required(24). Moreover, 
oral or topical corticosteroids in combination with oral antivirals are 
the treatment of choice for recurrent and chronic HZO(25). However, 
the role of steroids in the management of HZ is controversial(24), 
and the results of a systematic review of their efficacy are awaited. 
There fore, the use of corticosteroids to treat HZ without concomitant 
antiviral therapy is not recommended(23).
Following HZO, ocular complications associated with poor visual 
outcomes include acute corneal lesions, retinitis, optic neuritis, and uvei-
tis(26). Patients may also develop postherpetic neuralgia, scleritis, or 
ocular palsies(27). Overall, these may cause permanent visual loss and 
substantial health care utilization. Moreover, diseases in immunocom-
promised patients are unpredictable and associated with unfavorable 
outcomes(28).
VZV Vasculopathy
HZ infections were first discovered to be associated with neurologic 
VZV vasculopathy in 1919, when it was described as a late contra-
lateral hemiplegia following stroke(29). Since then, there have been 
numerous reports of infarcts in the cerebrum, cerebellum, midbrain, 
and pons after HZ or varicella infection(30). More recently, active viral 
infection has been shown in large and small arteries of patients with 
VZV vasculopathy(31), leading to the clinical spectrum expanding 
beyond typical hemiplegia to include other signs and symptoms, 
such as headache, fever, cognitive changes, transient ischemic attacks 
(TIAs), temporal arteritis(32), and focal neurologic deficits(17) (Table 2). 
However, specific vascular involvement varies widely, and associated 
TIAs may also evolve into a variety of vascular events, including single, 
bilateral, or multiple ischemic/hemorrhagic infarcts; aneurysms; cere-
bral or subarachnoid hemorrhages(33-35); or infarcts of the basal ganglia 
or internal capsule(36).
The mean time from onset of HZ to vasculopathy is unclear, and 
although it is typically described as 5-12 weeks(37,38), it can range from 
a day to 2.5 years(14,38,39). The diagnosis of VZV vasculopathy differs 
from that for either HZ or HZO infection in that it is based not only 
on clinical signs but also on the results of imaging and serological 
examinations. The criteria for magnetic resonance imaging rely on 
the identification of deep-seated infarcts at the junction of the gray 
and white matter. Magnetic resonance angiography can also show 
focal stenosis and beading(14,34), with multiple segmental narrowing 
of any artery on the ipsilateral side to the affected dermatome(35,40).
Screening for VZV vasculopathy is performed using either anti-VZV 
testing [immunoglobulin (Ig) M and IgG] or PCR of the CSF and serum. 
Nagel et al.(14) compared the sensitivities of these testing methods 
for VZV vasculopathy and found that only 30% of subjects had DNA 
positive for VZV in the CSF, whereas 93% had anti-VZV IgG in the CSF, 
indicating the significant superiority of VZV antibody testing.
VZV vasculopathy should be suspected in patients presenting with 
a recent episode of HZ and stroke(s) of undetermined origin, particu-
larly if the patient is immunocompromised. In addition, considering 
that 30% of patients have neither a rash nor CSF pleocytosis(14), the 
absence of a rash or the presence of normal CSF should not exclude 
the possibility of VZV vasculopathy. Recently, there have been reports 
of similar vascular events due to herpes simplex virus type 2 (HSV-2), 
and this should be considered in the differential diagnosis. Testing 
the CSF for HSV-2 DNA can help to differentiate one etiology from 
the other(41).
The vasculopathy mechanism was proposed initially as a varicella 
infection leading to a granulomatous angiitis(39,42,43). However, recent 
developments have shown evidence of direct VZV infection via 
ophthalmic branches the trigeminal nerve(44,45), which leads to trans-
mural spread from the adventitia and later disruption of the internal 
elastic lamina, intimal hypertrophy, and proinflammatory conditions 
- all of which are related to an increased risk of thrombotic events(16). 
Large and/or small vessels can be affected(46), in 50% of the cases both 
vessels are involved(16). (Figure 1).
Originally, the mechanism underlying vasculopathy was believed 
to be a result of varicella infection causing a granulomatous 
angiitis(39,42,43). However, recent developments have shown that there 
is direct VZV infection via the ophthalmic branches of the trigeminal 
nerve(44,45), which subsequently causes transmural spread from the 
adventitia that disrupts the internal elastic lamina, causes intimal 
hyper trophy, and promotes inflammatory conditions, all of which 

























Sclera Episcleritis Scleral atrophy and thinning
Scleritis
Uvea Uveitis Paralytic mydriasis
Hyphema Iris atrophy
Hypopyon Posterior synechiae
Retina Retinitis Cystoid macular edema
Acute retinal necrosis Retinal detachment
Progressive outer retina Retina atrophy
Necrosis




Paralysis of eye movement Strabismus
Diplopia
Vasculitis
Table 2. Warning signs and symptoms of zoster 
vasculopathy
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increase the risk of thrombotic events(14). Large or small vessels can be 
affected(46), and both vessels are involved in 50% of reported cases (14).
hZo and Vasculopathy: risk analysis
Major studies have been conducted to assess the relative risk of 
ischemic, thrombotic, or general vascular events related to zoster 
infections. Most agree there is a defined and significant risk among 
them(37,38,47,48), with general risk ratios ranging from 1.31 to 2.27(37,47,48). 
The risk ratios in these studies were extremely sensitive to the period 
after the zoster infection, zoster dermatome, treatment, and patient 
age at the time of infection.
When data obtained from patients with HZO were crossed with 
those of patients with vasculopathy events, the hazard ratios signi-
ficantly increased(38). A comparison between 658 patients with HZO 
with 1,974 controls showed that there was a mean 4.52-fold increased 
risk of stroke. Kang et al.(47) and Langan et al.(37) reported mean increa-
sed hazard risks of 4.59-and 3.38-fold, respectively, when they analyzed 
only patients with HZO. Overall, the evidence indicates that the first 
year after zoster infection is critical, being associated with the greatest 
increased risk of stroke among patients with both HZ and HZO. The ma-
ximal risk appears to fall within the first 3 months after zoster infection, 
when the mean risk ratios for HZ and HZO range from 0.99-fold(37) to 
2.27-fold(48) and from 0.82-fold(37) to 4.52-fold(38), respectively.
Multifocal temporal arteritis is another possible presentation of 
VZV vasculopathy. Termed multifocal VZV vasculopathy, it presents 
with the same clinical signs, symptoms, and laboratory findings as 
giant cells arteritis (GCA) and should be considered in cases of classic 
GCA where the temporal artery biopsy is negative(49).
Prompt diagnosis of VZV vasculopathy is imperative not only be-
cause it is a life-threatening condition with a mortality rate of 25%(50) if 
left untreated but also because the prognosis is benign when treated 
with intravenous acyclovir(51). Treatment typically involves 10-15 mg/kg 
of intravenous acyclovir three times daily for 10-14 days, with 1 mg/kg 
of prednisone administered intravenously or orally according to se-
verity(34,35). In most reports, corticosteroid use has resulted in either 
improvement or maintenance of the prognosis(52) (Table 3)(53,54).
COMMENT
Although the risk for VZV vasculopathy is often high in patients with 
HZO(37,38,48,55), several risk factors need to be considered when making 
an assessment. These include age, sex, body mass index, smoking 
status, and cholesterol levels, as well as the presence of comorbid 
hypertension, diabetes, and vascular and heart diseases. The absence 
of an adjusted analysis in some reports(38,48) may also have resulted in 
bias, such as selection based on the records of compatible treatments 
for HZ(48), or public medical records, which both may lead to misclassi-
fication of zoster types(37,38). Thus, it is not currently possible to confirm 
whether these risk factors increase the severity of HZ vasculopathy, 
whether patients with HZ vasculopathy have a higher incidence of 
these risk factors, whether these are also risk factors for HZ vasculo-
pathy, or whether there is any correlation between them.
Notwithstanding the disagreement among authors over whether 
the risk of VZV complications is directly attributable to VZV infection 
or whether they are merely independent vascular diseases associated 
with post-zoster infection, the severity of VZV vasculopathy should 
bring our attention to the need for a more aggressive HZ vaccination 
program. Indeed, HZ is preventable with vaccine administration(55), 
yet several authors only advocate HZ vaccination for patients with 
one episode of HZO(56), based on the rationale that most of these 
patients are older than 50 years and are already at an increased 
risk of vascular disease(57,58). However, this neglects the facts that 
prior vaccination reduces morbidity associated with HZ and is well 
tolerated(59). In general, primary care physicians usually recommend 
vaccination, but ophthalmologists may also need to play their role in 
preventing HZO. In the US, the cost of HZ vaccination was approxi-
mately $150 in 2009 (60), which limits general access. Although oral 
prophylaxis is routinely prescribed with either acyclovir or valacyclo-
vir, no evidence-based guidelines have been produced that support 
the prolonged use of suppressive antivirals for chronic HZO and its 
complications(61).
Despite the possible benefits of vaccination and its good safety 
profile, complications have been reported(62). Demyelinating central 
nervous system diseases are perhaps the most widely reported, and 
optic neuritis is the most prominent, with symptom onset ranging from 
several hours after vaccination to as late as 3 weeks. Although the prog-
nosis has been mostly good, several cases of poor visual outcomes 
have been reported(63). Other autoimmune diseases must also be 
considered in the differential diagnosis(64), including multiple sclerosis 
and neuromyelitis optica.
In this review, we analyzed the epidemiologic and clinical concepts 
of VZV infection and vasculopathy, and the peculiarities in relation to 
HZO. It is clear that VZV vasculopathy and HZO are related and that 
patients who present with HZO are at higher risk of developing VZV. 
However, making a diagnosis of VZV is not always easy, and it is essen-
tial that we educate the ophthalmology community on the systemic 
risks of VZV infections, particularly of stroke in patients with HZO. 
This is important because proper treatment with currently available 
antivirals can prevent death and provide better outcomes.
Preventing HZ vasculopathy is a controversial issue because it is 
not very prevalent. Nevertheless, a relative consensus agrees that 
vaccination may be important in preventing vascular events such as 
TIAs and strokes(37,57). In addition, because patients with HZO are already 
at an increased risk for vasculopathy, efforts should be made to reduce 
risk factors, including lifestyle habits such as smoking cessation as well 
as controlling obesity, cholesterol, and diabetes. Moreover, making a 
diagnosis of VZV vasculopathy is often complicated by the fact that 
neu rologic disease can develop weeks or months after an episode of 
herpes zoster; that not all patients have a history of rash or chickenpox; 
that vasculopathies of other origins produce the same clinical, CSF, and 
imaging abnormalities; and that virological analysis is often limited(14).
The considerations outlined in this review indicate the importance 
of ophthalmologists in the management of HZO. Follow-up visits for 
these patients must be frequent, and clinicians should be vigilant for 
symptoms of VZV vasculopathy. Ophthalmologists should be alert to 
the onset of neurological signs and instruct patients to report any 
changes because early systemic antiviral therapy is frequently asso-
ciated with a good prognosis.
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